# South Korea Type 1 Diabetes Treatment Market

> South Korea Type 1 Diabetes Treatment Market Research Report: By Treatment Type (Insulin Therapy, Continuous Glucose Monitoring, Insulin Pump Therapy, Immunotherapy), By Route of Administration (Subcutaneous, Intravenous, Inhalation), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), andBy Age Group (Children, Adolescents, Adults)- Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.56%
- **2018:** $ 209.25 Million
- **2024:** $ 0.22 Billion
- **2035:** $ 0.36 Billion
- **Key Players:** Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Roche (CH), Abbott (US), Merck (DE), Eli Lilly (US), Johnson & Johnson (US), Dexcom (US)

**Report ID:** MRFR/HC/49464-HCR · **Pages:** 200 · **Author:** Vikita Thakur · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-type-1-diabetes-treatment-market-51221

---

## Market Summary

**South Korea Type 1 Diabetes Treatment Market Overview:**

**As per MRFR analysis, the South Korea Type 1 Diabetes Treatment Market Size was estimated at 209.25 (USD Million) in 2023.****The South Korea Type 1 Diabetes Treatment****Market****is expected to grow from 234.8****(USD Million) in 2024 to 357.9 (USD Million) by 2035. The South Korea Type 1 Diabetes Treatment Market CAGR (growth rate) is expected to be around 3.906% during the forecast period (2025 - 2035).**

**Key South Korea Type 1 Diabetes Treatment Market Trends Highlighted**

The rising incidence of type 1 diabetes in children and adolescents is driving notable developments in the South Korean market for its treatment. The South Korean government is raising the bar for Type 1 diabetes care by investing more in diabetes care initiatives and research through the Health Insurance Review and Assessment Service.

Because it encourages the creation and accessibility of cutting-edge therapies like insulin pumps and continuous glucose monitoring systems, this dedication is a major market driver. Furthermore, there is a greater need for instructional materials and tools that promote self-management due to the growing awareness of diabetes management.

There are more opportunities in this sector, especially as digital health solutions become more popular. Patients are increasingly using mobile applications that assist them in monitoring their blood sugar levels, food consumption, and insulin use. Patients and their families can manage their diabetes more easily with the help of these convenient and supportive solutions.

Notable opportunities are also presented by the growing use of telemedicine services, which allow patients to consult with medical professionals from the convenience of their homes. This is especially advantageous in metropolitan regions where access to medical facilities may be restricted.

Personalised therapy and treatments designed especially for young patients with Type 1 diabetes have become popular in recent years. For example, patient care regimens include ongoing developments in insulin formulations and delivery techniques. This tendency contributes to better patient outcomes by reflecting a larger movement towards a more customised approach to diabetes care.

All things considered, the changing South Korean type 1 diabetes treatment market is a reflection of the nation's emphasis on improving patient education and healthcare delivery, which will eventually result in improved Type 1 diabetes management.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South Korea Type 1 Diabetes Treatment Market Drivers**

Increasing Prevalence of Type 1 Diabetes in South Korea

The South Korea Type 1 Diabetes Treatment Market is experiencing notable growth driven by the rising prevalence of Type 1 diabetes among the population. According to the Korea Diabetes Association, the number of diagnosed diabetes cases in South Korea was approximately 3.3 million in 2020, showing a significant increase in Type 1 diabetes cases, particularly among children and adolescents.

This trend is corroborated by reports indicating that the incidence rates of Type 1 diabetes in South Korea have been steadily rising, particularly in urban areas where lifestyle changes contribute to this rise.

The increasing number of patients requiring lifelong treatment is thus enhancing the demand for innovative treatment options. Established organizations such as the Ministry of Health and Welfare and the Korean Diabetes Association are dedicated to developing better treatment protocols and management systems for diabetes.

Their initiatives not only facilitate early diagnosis and patient education but also foster Research and Development (R&D) programs aimed at discovering more effective treatment modalities. As the awareness of diabetes and its complications grows, more individuals seek treatment, contributing to the market's expansion.

Advancements in Diabetes Treatment Technologies

Technological advancements in diabetes management tools, such as continuous glucose monitors and insulin pumps, are significant drivers of the South Korea Type 1 Diabetes Treatment Market. The Ministry of Food and Drug Safety in South Korea has seen an uptick in approvals for innovative diabetes management technologies, promoting better control of blood glucose levels among patients.

The market for such tools has expanded rapidly, with reports suggesting that the adoption of insulin pumps in South Korea increased by 23% between 2023 and 2021.

Organizations like Medtronic and Roche are at the forefront of these technological developments, continuously improving user experience and treatment adherence among Type 1 diabetes patients. As both healthcare providers and patients become more aware of the benefits of these advanced treatment options, the overall efficacy of diabetes management improves, fueling market growth.

Government Initiatives and Support for Diabetes Management

Government initiatives to enhance diabetes management and treatment access are significant contributors to the South Korea Type 1 Diabetes Treatment Market. The South Korean government has been actively implementing policies aimed at reducing diabetes prevalence, including comprehensive screenings and subsidizing medication costs.

Recent policies introduced by the Ministry of Health and Welfare aim to reduce out-of-pocket expenditures for diabetes treatment by 20%, enhancing accessibility for families managing Type 1 diabetes. Moreover, the Korean Diabetes Association actively collaborates with governmental bodies to organize educational campaigns focusing on diabetes care.

These initiatives are designed to improve the quality of care for patients while also increasing their participation in management programs. This collaborative approach fosters a supportive environment that promotes adherence to treatment regimens, thereby driving market growth as more patients gain access to the necessary resources.

Growing Public Awareness and Education on Diabetes

In South Korea, enhanced public awareness and education regarding diabetes have significantly influenced the South Korea Type 1 Diabetes Treatment Market. Awareness campaigns backed by both governmental bodies and NGOs have led to a better understanding of Type 1 diabetes and its implications.

Educational programs have reflected a proactive approach in dealing with diabetes, targeting schools and communities and emphasizing early detection and management. Surveys from the Korean Diabetes Association indicate that participation in diabetes education programs has risen by approximately 40% over the past five years, reflecting an engaged population ready to adopt healthier lifestyles.

Established organizations play a vital role in disseminating information, thereby leading to an increase in early diagnoses and subsequent treatment requirements. This growth in awareness translates into higher demand for diabetes treatments and monitoring tools as patients become more informed about managing their conditions effectively.

**South Korea Type 1 Diabetes Treatment Market Segment Insights:**

**Type 1 Diabetes Treatment Market Treatment Type Insights**

The South Korea Type 1 Diabetes Treatment Market is characterized by a diverse range of treatment types tailored to manage this chronic condition effectively. Among these, Insulin Therapy stands out as the cornerstone for most patients, playing a crucial role in regulating blood glucose levels and minimizing complications associated with diabetes.

This method allows for personalized dosing, which is essential in the management of Type 1 Diabetes. Continuous Glucose Monitoring is gaining traction, as it provides real-time data, allowing patients and healthcare providers to make informed decisions regarding insulin administration and lifestyle choices.

This segment enhances the quality of life for individuals, as timely adjustments can be made based on fluctuating glucose levels, ultimately leading to better health outcomes. Insulin Pump Therapy has also gained significant attention due to its convenience and ability to deliver precise insulin doses throughout the day, minimizing the burden on patients.

This technology represents a shift towards more automated forms of diabetes management, thus catering to the growing demand for innovative solutions in the healthcare landscape. Meanwhile, Immunotherapy is emerging as a novel treatment option, focusing on the underlying autoimmune aspects of Type 1 Diabetes.

By addressing the immune system's role in the disease process, this approach holds the potential to alter the course of the disease, offering hope for better long-term outcomes.

The segmentation of the South Korea Type 1 Diabetes Treatment Market reflects evolving treatment philosophies that prioritize patient-centric care and precision medicine, catering to the unique needs of the Type 1 Diabetes population within the region.

As such, advances in these treatment types reflect broader trends towards personalized medicine, leading to improved management strategies and overall population health in South Korea.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Type 1 Diabetes Treatment Market Route of Administration Insights**

The Route of Administration within the South Korea Type 1 Diabetes Treatment Market plays a pivotal role in determining the efficacy and patient adherence to treatment protocols. This segment comprises several key methods, including Subcutaneous, Intravenous, and Inhalation delivery systems.

Subcutaneous administration is particularly significant as it allows for self-injection and improved patient compliance, making it a popular choice among many individuals managing Type 1 Diabetes. Intravenous delivery, while less common for ongoing treatment, is crucial in acute care settings where quick onset of action is necessary.

Inhalation methods represent an innovative approach, potentially enhancing delivery efficiency and user-friendliness. With advancements in technology and increased awareness of diabetes management, the demand for effective and convenient routes of administration is expected to support the growth of this segment.

Overall, understanding the dynamics within the Route of Administration not only sheds light on the current landscape but also provides insights into future trends in the South Korea Type 1 Diabetes Treatment Market.

**Type 1 Diabetes Treatment Market Distribution Channel Insights**

The South Korea Type 1 Diabetes Treatment Market demonstrates a robust distribution channel landscape, prominently featuring Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Each of these channels plays a crucial role in ensuring accessible treatment for patients across the nation.

Hospital Pharmacies are often regarded as integral to patient care, providing specialized diabetes medications and ensuring that patients receive comprehensive management alongside clinical services. Retail Pharmacies, on the other hand, serve as key touchpoints for patients, offering convenience and readily available treatments, which can significantly influence adherence to prescribed therapies.

Furthermore, the rise of Online Pharmacies marks a transformative shift in how patients access medications, driven by the growing trend toward digital health solutions and e-commerce in South Korea. This channel caters to a tech-savvy population, allowing for easy ordering and home delivery, ultimately enhancing patient convenience and adherence.

Overall, the interplay of these channels reflects the evolving dynamics of the healthcare sector in South Korea, ensuring that diabetes patients receive timely and appropriate treatment through various accessible avenues. Growing initiatives and government support for diabetes care further bolster these distribution channels, addressing the healthcare needs of this population.

**Type 1 Diabetes Treatment Market Age Group Insights**

The South Korea Type 1 Diabetes Treatment Market is significantly influenced by the Age Group demographic, which is crucial for tailoring treatment pathways. This market segment includes Children, Adolescents, and Adults, each presenting distinct challenges and treatment needs.

The Children demographic is essential as early intervention can lead to better health outcomes and helps prevent complications later in life. In contrast, the Adolescents face unique obstacles, such as the transition from pediatric to adult care, which can affect their disease management and adherence.

Adults, on the other hand, generally require lifelong management strategies, thus representing a substantial portion of the market. Moreover, advancements in insulin delivery systems, continuous glucose monitoring, and educating caregivers and patients across these age groups play a vital role in the market's expansion.

Increasing awareness and government initiatives pertaining to diabetes education aid in enhancing the effectiveness of treatments across all age categories. This collective focus on the Age Group segments not only reflects significant market growth prospects but also emphasizes the ongoing need for tailored therapies that align with the diverse requirements of individuals through their life stages.

**South Korea Type 1 Diabetes Treatment Market Key Players and Competitive Insights:**

The South Korea Type 1 Diabetes Treatment Market has been experiencing notable developments and growing competition, driven by an increasing prevalence of diabetes within the population and heightened awareness of treatment options among patients and healthcare providers.

The market comprises various stakeholders, including pharmaceutical companies, medical device manufacturers, healthcare institutions, and regulatory bodies, all vying for a share in this expanding sector.

Companies are innovating to offer advanced therapies and technologies that enhance patient care and improve quality of life, leading to an energetic yet competitive environment. The focus on personalized medicine and the push for effective management solutions are key trends influencing competitive strategies as organizations aim to differentiate their offerings.

MannKind Corporation has established a significant presence in the South Korea Type 1 Diabetes Treatment Market through its advanced insulin delivery solutions. The company is recognized for its unique inhaled insulin product, which offers an alternative to traditional injection-based therapies.

MannKind Corporation capitalizes on its innovative technology that provides a non-invasive approach to insulin administration, thereby targeting patient preferences for convenience and efficacy. The firm’s strengths lie in its commitment to research and development, which has enabled it to cater to the needs of Type 1 diabetes patients more effectively.

The collaboration with local distributors and healthcare providers enhances their operational efficiency as they strive to penetrate deeper into the South Korean market, addressing the diverse needs of diabetic patients in the region.

Eli Lilly stands as a prominent player in the South Korea Type 1 Diabetes Treatment Market with a robust portfolio of insulin products and diabetes management solutions. The company is known for its long-acting and rapid-acting insulin formulations that are widely used in diabetes care.

Eli Lilly’s strengths include a well-established brand presence and extensive distribution networks, allowing for better accessibility to its therapies. Additionally, the organization has engaged in strategic partnerships and collaborations aimed at enhancing its product offerings and improving patient adherence.

Eli Lilly has also pursued mergers and acquisitions to broaden its technological capabilities and expand its market reach, specifically tailoring solutions for the South Korean population. The company's continual investment in research initiatives reinforces its commitment to advancing diabetes care, solidifying its position as a leader in addressing the needs of patients living with Type 1 diabetes in South Korea.

**Key Companies in the South Korea Type 1 Diabetes Treatment Market Include:**

MannKind Corporation

Eli Lilly

Roche

Johnson & Johnson

Diabetes Australia

Pfizer

Novo Nordisk

Bristol-Myers Squibb

Merck

Amgen

AstraZeneca

Takeda Pharmaceutical

AbbVie

Sanofi

Boehringer Ingelheim

**South Korea Type 1 Diabetes Treatment****Market****Developments**

_The South Korea Type 1 Diabetes Treatment Market has witnessed significant developments recently, particularly in terms of growth and innovations. In August 2023, Eli Lilly launched its new insulin product in the South Korean market, aiming to enhance patient outcomes and treatment adherence._

_Additionally, Novo Nordisk is actively expanding its market presence by partnering with local healthcare providers to promote its diabetes care solutions. Recent reports indicate that there has been a remarkable increase in the market valuation for companies like Johnson and Johnson and Roche, attributed to the rising prevalence of diabetes in South Korea and growing awareness of management options._

_Moreover, in September 2023, Pfizer announced a strategic collaboration with a local firm to research more effective Type 1 diabetes treatments. Notably, Merck and Takeda Pharmaceutical are also focusing on Research and Development initiatives to innovate in the treatment landscape._

_The South Korean government continues to prioritize diabetes care through initiatives to improve healthcare access and education, reflecting a supportive environment for pharmaceutical advancements in managing Type 1 diabetes. The evolving market dynamics and corporate strategies are shaping a more competitive landscape that is conducive to improved patient outcomes and healthcare equality._

**South Korea Type 1 Diabetes Treatment Market Segmentation Insights**

**Type 1 Diabetes Treatment Market Treatment Type****Outlook**

**Insulin Therapy**

**Continuous Glucose Monitoring**

**Insulin Pump Therapy**

**Immunotherapy**

**Type 1 Diabetes Treatment Market Route of Administration****Outlook**

**Subcutaneous**

**Intravenous**

**Inhalation**

**Type 1 Diabetes Treatment Market Distribution Channel****Outlook**

**Hospital Pharmacy**

**Retail Pharmacy**

**Online Pharmacy**

**Type 1 Diabetes Treatment Market Age Group****Outlook**

**Children**

**Adolescents**

**Adults**

## Market Drivers

### Government Initiatives and Support

Government policies and initiatives aimed at improving diabetes care significantly influence the South Korea Type 1 Diabetes Treatment Market. The South Korean government has implemented various programs to enhance diabetes management, including subsidized insulin and glucose monitoring devices. These initiatives are designed to alleviate the financial burden on patients and encourage adherence to treatment regimens. Additionally, public health campaigns aimed at educating the population about diabetes prevention and management are likely to foster a more informed patient base. As a result, the South Korea Type 1 Diabetes Treatment Market is poised for growth, supported by favorable government policies that promote access to essential diabetes care.

### Rising Demand for Personalized Medicine

The shift towards personalized medicine is becoming a prominent trend within the South Korea Type 1 Diabetes Treatment Market. Patients are increasingly seeking tailored treatment plans that consider their unique genetic, environmental, and lifestyle factors. This demand for individualized care is prompting healthcare providers to adopt more comprehensive approaches to diabetes management. As a result, pharmaceutical companies are investing in research to develop targeted therapies that cater to specific patient needs. The growing emphasis on personalized medicine is expected to drive innovation and enhance treatment outcomes, thereby contributing to the expansion of the South Korea Type 1 Diabetes Treatment Market.

### Increasing Prevalence of Type 1 Diabetes

The rising incidence of Type 1 diabetes in South Korea is a pivotal driver for the South Korea Type 1 Diabetes Treatment Market. Recent statistics indicate that the prevalence of Type 1 diabetes among children and adolescents has been steadily increasing, with estimates suggesting that approximately 1 in 400 children are affected. This growing patient population necessitates enhanced treatment options and management strategies, thereby propelling market growth. Furthermore, the increasing awareness of diabetes management among healthcare professionals and patients is likely to contribute to the demand for innovative treatment solutions. As the healthcare system adapts to this rising prevalence, the South Korea Type 1 Diabetes Treatment Market is expected to expand, driven by the need for effective therapies and support systems.

### Technological Advancements in Treatment Options

Technological innovations in diabetes treatment are transforming the landscape of the South Korea Type 1 Diabetes Treatment Market. The introduction of advanced insulin delivery systems, such as insulin pumps and smart pens, has revolutionized the way patients manage their condition. Moreover, the integration of artificial intelligence in diabetes management tools is enhancing personalized treatment plans. According to recent data, the market for insulin delivery devices is projected to grow significantly, driven by these technological advancements. As patients increasingly seek more effective and convenient treatment options, the South Korea Type 1 Diabetes Treatment Market is likely to experience substantial growth, fueled by ongoing research and development in diabetes technologies.

### Growing Awareness and Education on Diabetes Management

The increasing awareness and education surrounding diabetes management are crucial drivers for the South Korea Type 1 Diabetes Treatment Market. Educational initiatives aimed at both healthcare professionals and patients are fostering a better understanding of Type 1 diabetes and its management. This heightened awareness is likely to lead to improved treatment adherence and better health outcomes. Furthermore, community support programs and workshops are empowering patients to take control of their condition. As the population becomes more informed about diabetes management strategies, the South Korea Type 1 Diabetes Treatment Market is expected to grow, driven by the demand for effective treatment solutions and support services.

## Future Outlook

The South Korea Type 1 Diabetes Treatment Market is projected to grow at a 4.56% CAGR from 2024 to 2035, driven by technological advancements, increasing prevalence, and enhanced patient management solutions.

**New opportunities:**

- Development of personalized insulin delivery systems
- Expansion of telehealth services for diabetes management
- Investment in AI-driven predictive analytics for treatment optimization

By 2035, the market is expected to be robust, driven by innovation and increased patient engagement.

## Segment Insights

### By Treatment Type: Insulin Therapy (Largest) vs. Continuous Glucose Monitoring (Fastest-Growing)

In the South Korea Type 1 Diabetes Treatment Market, Insulin Therapy remains the largest segment, commanding a significant share of the treatment landscape. This traditional approach has been widely adopted due to its long-standing effectiveness in managing Type 1 diabetes. Continuous Glucose Monitoring (CGM) is emerging strongly, capturing attention for its innovative technology that enhances patient convenience and control. This segment's market share continues to grow as more patients and healthcare professionals recognize the benefits of real-time glucose tracking.

Growth trends indicate a robust shift towards digital health solutions, with Continuous Glucose Monitoring leading this transformation. The increasing prevalence of Type 1 diabetes, coupled with rising healthcare awareness, is driving the demand for innovative treatment options. Insulin Pumps and Diabetes Management Software are also gaining traction; however, their growth rates are currently overshadowed by the rapid acceptance of CGM technology among both patients and clinicians.

Insulin Therapy (Dominant) vs. Diabetes Management Software (Emerging)

Insulin Therapy holds a dominant position in the South Korea Type 1 Diabetes Treatment Market due to its proven effectiveness in managing blood glucose levels over the years. Patients are well-acquainted with this method, often relying on prescribed insulin regimens to stabilize their condition. Conversely, Diabetes Management Software is emerging as an innovative tool that integrates technology into diabetes care. This software enables meticulous tracking of glucose levels, insulin doses, and dietary habits, empowering patients to take a proactive role in their management. While Insulin Therapy is essential and deeply rooted in treatment protocols, the growing inclination towards digital solutions signifies a shift that could redefine patient engagement and disease management in the coming years.

### By Patient Age Group: Children (Largest) vs. Adults (Fastest-Growing)

In the South Korea Type 1 Diabetes Treatment Market, the patient age group segmentation reveals that children constitute the largest share, receiving considerable attention from healthcare providers and stakeholders. This demographic is crucial as they require specialized management for T1D from an early age. Conversely, the adult segment is witnessing rapid expansion, reflecting the rising awareness and early diagnosis of Type 1 Diabetes in adults, leading to increased treatment adoption among this age group.

Children: Largest vs. Adults: Fastest-Growing

Children represent the largest segment in the South Korea Type 1 Diabetes Treatment Market due to targeted healthcare solutions tailored to their needs. These include insulin therapy, continuous glucose monitoring, and educational programs involving family members for comprehensive management. On the other hand, adults are emerging as the fastest-growing group, largely driven by initiatives promoting awareness of T1D and the availability of innovative treatment protocols. This trend indicates a shift towards recognizing the condition in older age groups, leading to a diverse market landscape catering to their specific health requirements.

### By Administration Route: Subcutaneous Injection (Largest) vs. Intravenous Injection (Fastest-Growing)

In the South Korea Type 1 Diabetes Treatment Market, the administration route is a pivotal factor influencing treatment adherence and patient outcomes. Currently, subcutaneous injection holds the largest market share, as it is the most commonly used method due to its ease of use and patient familiarity. Conversely, intravenous injection, while less common, is rapidly gaining traction among healthcare providers as a more immediate solution for acute management, particularly in hospital settings. 

Growth trends in this segment are driven by technological advancements and the introduction of user-friendly devices. Subcutaneous injectors equipped with smart technologies are enhancing patient compliance, while intravenous methods are being recognized for their efficacy in critical care scenarios. The increasing prevalence of Type 1 diabetes is also prompting innovations and expansions in administration technologies, fueling market growth in this area.

Administration Route: Subcutaneous Injection (Dominant) vs. Intravenous Injection (Emerging)

Subcutaneous injection is the dominant administration route in the South Korea Type 1 Diabetes Treatment Market, favored for its simplicity and flexibility, allowing patients to self-administer insulin with relative ease. Devices such as insulin pens have revolutionized this administration method, making it convenient for daily use. In contrast, intravenous injection is emerging as a vital alternative, primarily used in hospital settings for more severe cases or when rapid insulin delivery is required. The emergence of this route is driven by its potential to deliver insulin more efficiently during acute episodes, reflecting a growing acceptance and innovation in diabetes treatment protocols.

### By Healthcare Setting: Hospitals (Largest) vs. Telehealth (Fastest-Growing)

The South Korea Type 1 Diabetes Treatment Market showcases a diversified landscape across various healthcare settings. Hospitals represent the largest segment, accounting for a significant portion of the market share due to their advanced facilities and specialized care for diabetes management. Clinics also hold a notable share, providing focused outpatient services that cater to individuals with Type 1 Diabetes. In contrast, Home Care and Telehealth segments are emerging, reflecting a shift towards more accessible and patient-centered care models.

Clinics (Dominant) vs. Telehealth (Emerging)

In the South Korea Type 1 Diabetes Treatment Market, Hospitals are recognized as the dominant force due to their comprehensive resources and expert medical teams, ensuring intensive care and management plans for patients. Clinics, while also dominant, serve as essential touchpoints for regular monitoring and ongoing therapy. On the other hand, Telehealth is emerging rapidly, driven by advances in technology and increasing consumer preferences for remote consultations and digital health solutions. This growth is fueled by the convenience offered to patients, enabling them to manage their condition effectively from home, thus complementing traditional clinical practices.

## Competitive Benchmarking

The South Korea Type 1 Diabetes Treatment Market exhibits a dynamic competitive landscape characterized by innovation and strategic partnerships. Key players such as Novo Nordisk (DK), Sanofi (FR), and Eli Lilly (US) are actively shaping the market through their focus on advanced treatment options and patient-centric solutions. Novo Nordisk (DK) emphasizes its commitment to research and development, particularly in insulin delivery systems, while Sanofi (FR) leverages its extensive portfolio to enhance patient access to therapies. Eli Lilly (US) is increasingly investing in digital health solutions, indicating a shift towards integrated care models. Collectively, these strategies foster a competitive environment that prioritizes innovation and patient engagement.

In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they drive advancements in treatment methodologies and patient care. This competitive structure suggests that while there is room for smaller entities, the dominance of established firms shapes the overall market dynamics.

In January 2026, Novo Nordisk (DK) announced a partnership with a local technology firm to develop a new digital platform aimed at improving diabetes management. This strategic move is likely to enhance patient engagement and adherence to treatment protocols, reflecting a broader trend towards integrating technology in healthcare. Such initiatives may position Novo Nordisk (DK) as a leader in the digital transformation of diabetes care in South Korea.

In December 2025, Sanofi (FR) launched a new insulin formulation designed to provide more flexible dosing options for patients. This innovation is significant as it addresses the growing demand for personalized treatment regimens, potentially improving patient outcomes and satisfaction. By focusing on patient needs, Sanofi (FR) reinforces its competitive edge in the market.

In November 2025, Eli Lilly (US) expanded its collaboration with local healthcare providers to enhance access to its diabetes therapies. This strategic action underscores the importance of partnerships in navigating the complex healthcare landscape in South Korea. By fostering relationships with healthcare professionals, Eli Lilly (US) is likely to strengthen its market presence and improve patient access to its innovative treatments.

As of February 2026, current competitive trends in the South Korea Type 1 Diabetes Treatment Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming pivotal in shaping the landscape, as companies seek to leverage each other's strengths to enhance patient care. Looking ahead, competitive differentiation is expected to evolve, with a pronounced shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable healthcare ecosystem.

## Report Scope

Report Scope: 

| Report Attribute/Metric Source: | Details |
| --- | --- |
| MARKET SIZE 2018 | 209.25(USD Million) |
| MARKET SIZE 2024 | 234.8(USD Million) |
| MARKET SIZE 2035 | 357.9(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.906% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | MannKind Corporation, Eli Lilly, Roche, Johnson & Johnson, Diabetes Australia, Pfizer, Novo Nordisk, BristolMyers Squibb, Merck, Amgen, AstraZeneca, Takeda Pharmaceutical, AbbVie, Sanofi, Boehringer Ingelheim |
| SEGMENTS COVERED | Treatment Type, Route of Administration, Distribution Channel, Age Group |
| KEY MARKET OPPORTUNITIES | Technological advancements in diabetes devices, Increased awareness and education programs, Expansion of telehealth services, Innovative insulin delivery systems, Government support for diabetes research |
| KEY MARKET DYNAMICS | increasing diabetes prevalence, advanced treatment technologies, government healthcare policies, insulin accessibility, patient education programs |
| COUNTRIES COVERED | South Korea |

## Frequently Asked Questions

**Q: What is the current valuation of the South Korea Type 1 Diabetes Treatment Market?**
A: As of 2024, the market valuation was 0.219 USD Billion.

**Q: What is the projected market size for the South Korea Type 1 Diabetes Treatment Market by 2035?**
A: The market is expected to reach a valuation of 0.357 USD Billion by 2035.

**Q: What is the expected CAGR for the South Korea Type 1 Diabetes Treatment Market during the forecast period?**
A: The market is projected to grow at a CAGR of 4.56% from 2025 to 2035.

**Q: Which companies are the key players in the South Korea Type 1 Diabetes Treatment Market?**
A: Key players include Novo Nordisk, Sanofi, Boehringer Ingelheim, Roche, Abbott, Merck, Eli Lilly, Johnson & Johnson, and Dexcom.

**Q: What are the main treatment types in the South Korea Type 1 Diabetes Treatment Market?**
A: The main treatment types include Insulin Therapy, Continuous Glucose Monitoring, Insulin Pumps, and Diabetes Management Software.

**Q: How did the Insulin Therapy segment perform in 2024?**
A: In 2024, the Insulin Therapy segment was valued at approximately 0.085 USD Billion.

**Q: What is the projected growth for the Continuous Glucose Monitoring segment by 2035?**
A: The Continuous Glucose Monitoring segment is expected to grow from 0.065 USD Billion in 2024 to 0.107 USD Billion by 2035.

**Q: Which patient age group is expected to contribute the most to the market by 2035?**
A: Adults are projected to contribute the most, with a market value expected to rise from 0.08 USD Billion in 2024 to 0.13 USD Billion by 2035.

**Q: What administration routes are utilized in the South Korea Type 1 Diabetes Treatment Market?**
A: Administration routes include Subcutaneous Injection, Intravenous Injection, Inhalation, and Transdermal methods.

**Q: How is the market segmented by healthcare setting in 2024?**
A: In 2024, the market was segmented into Hospitals, Clinics, Home Care, and Telehealth, with Hospitals valued at 0.087 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-type-1-diabetes-treatment-market-51221*